000277806 001__ 277806
000277806 005__ 20240229162349.0
000277806 0247_ $$2doi$$a10.1016/j.ctro.2023.100653
000277806 0247_ $$2pmid$$apmid:37502699
000277806 0247_ $$2pmc$$apmc:PMC10369398
000277806 037__ $$aDKFZ-2023-01517
000277806 041__ $$aEnglish
000277806 082__ $$a610
000277806 1001_ $$0P:(DE-HGF)0$$aEhret, Felix$$b0
000277806 245__ $$aOutcomes of Isocitrate Dehydrogenase Wild Type Glioblastoma after Re-irradiation.
000277806 260__ $$aAmsterdam$$bElsevier$$c2023
000277806 3367_ $$2DRIVER$$aarticle
000277806 3367_ $$2DataCite$$aOutput Types/Journal article
000277806 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1690549497_11047
000277806 3367_ $$2BibTeX$$aARTICLE
000277806 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000277806 3367_ $$00$$2EndNote$$aJournal Article
000277806 520__ $$aGlioblastomas (GBM) are the most common malignant primary brain tumors in adults and have a dismal prognosis. Patients frequently suffer from local tumor recurrences, with limited therapeutic options. Re-irradiation represents a possible intervention, but given the recent 5th edition of the World Health Organization classification of central nervous system tumors, studies in isocitrate dehydrogenase wild type (IDH-wt) cohorts undergoing a second course of radiotherapy remain limited. Herein, we sought to describe our institutional experience and outcomes after GBM IDH-wt re-irradiation.GBM patients with confirmed IDH-wt status undergoing re-irradiation were included in this single-center, retrospective analysis.A total of 88 patients were analyzed. The median clinical and radiographic follow-up periods were 4.6 months and 4.4 months, respectively. Most patients had a Karnofsky performance status of at least 80% (n = 57). The median biologically effective dose and 2 Gy equivalent dose (EQD2) for re-irradiations, assuming an α/β ratio of 10 Gy for GBM, were 51.4 and 42.8 Gy, respectively. In total, 71 deaths were recorded. The median overall survival (OS) was 8.0 months. Multivariable Cox regression of OS revealed a positive influence of gross total resection vs. biopsy or no resection (hazard ratio: 0.43, p = 0.02). The median progression-free survival (PFS) was 5.9 months. The multivariable Cox regression for PFS did not detect any significant factors. No clear evidence of radiation necrosis was recorded during the available follow-up. However, only a minority (n = 4) of patients underwent surgery after re-irradiation, none showing histopathological proof of radiation necrosis.The prognosis for recurrent IDH-wt GBM after re-irradiation is poor. Patients who are amenable and able to undergo re-resection may have a favorable OS. A second course of radiotherapy with a moderate cumulative EQD2 and small- to medium-sized planning target volumes appeared safe regarding the occurrence of radiation necrosis.
000277806 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000277806 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000277806 650_7 $$2Other$$aGlioblastoma
000277806 650_7 $$2Other$$aIDH
000277806 650_7 $$2Other$$aIsocitrate Dehydrogenase
000277806 650_7 $$2Other$$aRadiation Necrosis
000277806 650_7 $$2Other$$aRadionecrosis
000277806 650_7 $$2Other$$aRadiotherapy
000277806 650_7 $$2Other$$aRe-irradiation
000277806 7001_ $$aWolfgang, Josy$$b1
000277806 7001_ $$aAllwohn, Luisa$$b2
000277806 7001_ $$aOnken, Julia$$b3
000277806 7001_ $$aWasilewski, David$$b4
000277806 7001_ $$0P:(DE-HGF)0$$aRoohani, Siyer$$b5
000277806 7001_ $$aOertel, Joachim$$b6
000277806 7001_ $$0P:(DE-HGF)0$$aZips, Daniel$$b7
000277806 7001_ $$0P:(DE-HGF)0$$aKaul, David$$b8
000277806 773__ $$0PERI:(DE-600)2885426-3$$a10.1016/j.ctro.2023.100653$$gVol. 42, p. 100653 -$$p100653$$tClinical and translational radiation oncology$$v42$$x2405-6308$$y2023
000277806 909CO $$ooai:inrepo02.dkfz.de:277806$$pVDB
000277806 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000277806 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000277806 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000277806 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000277806 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000277806 9141_ $$y2023
000277806 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-16
000277806 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-16
000277806 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-16
000277806 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-16
000277806 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN TRANSL RAD ONCO : 2022$$d2023-08-23
000277806 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-23
000277806 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-23
000277806 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-23
000277806 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T14:51:10Z
000277806 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T14:51:10Z
000277806 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T14:51:10Z
000277806 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-23
000277806 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-23
000277806 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-23
000277806 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-23
000277806 9201_ $$0I:(DE-He78)BE01-20160331$$kBE01$$lDKTK Koordinierungsstelle Berlin$$x0
000277806 980__ $$ajournal
000277806 980__ $$aVDB
000277806 980__ $$aI:(DE-He78)BE01-20160331
000277806 980__ $$aUNRESTRICTED